OnyemaEberechukwuOgbuaguMD
Infectious Disease • New Haven, CTAssistant Professor, Internal Medicine, Yale University School of Medicine
Are you Dr. Ogbuagu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-688-6959
Summary
- Dr. Onyema Ogbuagu, MD is an infectious disease specialist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut and New York. He is affiliated with Yale-New Haven Hospital and MidState Medical Center.
Education & Training
Yale-New Haven Medical CenterFellowship, Infectious Disease, 2010 - 2012
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2006 - 2010
University of Calabar Faculty of MedicineClass of 2003
Certifications & Licensure
CT State Medical License 2011 - 2025
NY State Medical License 2010 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.Onyema E Ogbuagu, Anchalee Avihingsanon, Sorana Segal-Maurer, Hui Wang, Vamshi K Jogiraju
AIDS. 2025-02-05 - Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years.Nicolas A Margot, Vamshi Jogiraju, Nina Pennetzdorfer, Vidula Naik, Laurie A VanderVeen
The Journal of Infectious Diseases. 2025-01-28 - Drug interactions in people with HIV treated with antivirals for other viral illnesses.Adaora Okoli, Onyema Ogbuagu
Expert Opinion on Drug Metabolism & Toxicology. 2025-01-23
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Join now to see all
Press Mentions
Questioning if It Is Too Late to Get a COVID Vaccine Earlier Than Thanksgiving? Learn ThisNovember 26th, 2024- Wondering if It's Too Late to Get a COVID Vaccine Before Thanksgiving? Read ThisNovember 25th, 2024
- Twice-Yearly Injection Cuts HIV Risk by 96%, but Will Cost Cut Access?September 13th, 2024
- Join now to see all
